[
  {
    "ts": null,
    "headline": "Lilly to participate in Citi's 2025 Global Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=b0b3018c6581886ca33c9237f59b8b7865680daa3d7e60f3e3266f7dea7e7da8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763478000,
      "headline": "Lilly to participate in Citi's 2025 Global Healthcare Conference",
      "id": 137538222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=b0b3018c6581886ca33c9237f59b8b7865680daa3d7e60f3e3266f7dea7e7da8"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Comments On Eli Lilly (LLY)’s Shares After Pfizer CEO’s Remarks",
    "summary": "We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s attention. Throughout 2025, the CNBC TV host […]",
    "url": "https://finnhub.io/api/news?id=508fdfc2f2fd6bb6b38cace0772b4ee501d4153354ca6f17a40c70a457cc728a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763473511,
      "headline": "Jim Cramer Comments On Eli Lilly (LLY)’s Shares After Pfizer CEO’s Remarks",
      "id": 137538223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s attention. Throughout 2025, the CNBC TV host […]",
      "url": "https://finnhub.io/api/news?id=508fdfc2f2fd6bb6b38cace0772b4ee501d4153354ca6f17a40c70a457cc728a"
    }
  },
  {
    "ts": null,
    "headline": "WW International: First Normal Quarter Shows Signs Of Stability",
    "summary": "WW International is stabilizing their business after a voluntary chapter 11 filing, and Clinical growth appears on track to driving top line growth again in 2H-26.",
    "url": "https://finnhub.io/api/news?id=275ed28056036d2da6362a7437d9367dd8f4b9b0fb613d133fc9ef3f7f228546",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763471003,
      "headline": "WW International: First Normal Quarter Shows Signs Of Stability",
      "id": 137539982,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/501133597/image_501133597.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "WW International is stabilizing their business after a voluntary chapter 11 filing, and Clinical growth appears on track to driving top line growth again in 2H-26.",
      "url": "https://finnhub.io/api/news?id=275ed28056036d2da6362a7437d9367dd8f4b9b0fb613d133fc9ef3f7f228546"
    }
  },
  {
    "ts": null,
    "headline": "This Market Selloff Has Engulfed Stocks, Crypto, Gold. How the Fed Can Stop It.",
    "summary": "Crypto caught in broad market selloff, food, restaurant companies feeling relief, U.S.-China trade deal is fragile, and more news to start your day.",
    "url": "https://finnhub.io/api/news?id=6738109874e9048ab470047b0b5eec466dbc5d1ae105c36d7ad20874283a7a76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763465880,
      "headline": "This Market Selloff Has Engulfed Stocks, Crypto, Gold. How the Fed Can Stop It.",
      "id": 137538224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Crypto caught in broad market selloff, food, restaurant companies feeling relief, U.S.-China trade deal is fragile, and more news to start your day.",
      "url": "https://finnhub.io/api/news?id=6738109874e9048ab470047b0b5eec466dbc5d1ae105c36d7ad20874283a7a76"
    }
  },
  {
    "ts": null,
    "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
    "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
    "url": "https://finnhub.io/api/news?id=2f619276006f59ef7f4326c21becb1df015e7eb3446155dcf003afb73f07c53a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763461800,
      "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
      "id": 137538225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
      "url": "https://finnhub.io/api/news?id=2f619276006f59ef7f4326c21becb1df015e7eb3446155dcf003afb73f07c53a"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
    "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
    "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763460874,
      "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
      "id": 137538047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412857430/image_1412857430.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
      "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de"
    }
  },
  {
    "ts": null,
    "headline": "Baron Opportunity Fund Q3 2025 Portfolio Update",
    "summary": "This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises.",
    "url": "https://finnhub.io/api/news?id=df4f7d93fdb6fd8a1226a5a3ec195a92dae2c91f1cfbe767ea62dcaf507af0b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763460360,
      "headline": "Baron Opportunity Fund Q3 2025 Portfolio Update",
      "id": 137537990,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2234269213/image_2234269213.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises.",
      "url": "https://finnhub.io/api/news?id=df4f7d93fdb6fd8a1226a5a3ec195a92dae2c91f1cfbe767ea62dcaf507af0b9"
    }
  },
  {
    "ts": null,
    "headline": "TD Cowen Maintains Buy on Eli Lilly (LLY) After Government Deal",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $960. This update came after the company announced an agreement with the US government to expand access […]",
    "url": "https://finnhub.io/api/news?id=90755488cd720be494c37dc0356928a4696182a8838b4c34bff2c4e4e3a0a45e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763459147,
      "headline": "TD Cowen Maintains Buy on Eli Lilly (LLY) After Government Deal",
      "id": 137538226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $960. This update came after the company announced an agreement with the US government to expand access […]",
      "url": "https://finnhub.io/api/news?id=90755488cd720be494c37dc0356928a4696182a8838b4c34bff2c4e4e3a0a45e"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum",
    "summary": "Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.",
    "url": "https://finnhub.io/api/news?id=0f44308c847b02b8a6c83cff8c6d58316ba5a840e96deba9937d471caa822371",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763458020,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum",
      "id": 137538227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.",
      "url": "https://finnhub.io/api/news?id=0f44308c847b02b8a6c83cff8c6d58316ba5a840e96deba9937d471caa822371"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb Remains Undervalued In 2025",
    "summary": "Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.",
    "url": "https://finnhub.io/api/news?id=ef870d0978205ddbda040a9c799af982910929083ae52e5bd46e2219a463e9b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763457986,
      "headline": "Why Bristol-Myers Squibb Remains Undervalued In 2025",
      "id": 137537841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/937153960/image_937153960.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.",
      "url": "https://finnhub.io/api/news?id=ef870d0978205ddbda040a9c799af982910929083ae52e5bd46e2219a463e9b2"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Novo Nordisk: “You Gotta Let It Come Back a Little”",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder of substantial NVO shares that have significantly declined in value, if it is too late to exit the position. In response, Mad Money’s host said: “You gotta, okay, you gotta let it come […]",
    "url": "https://finnhub.io/api/news?id=ff3a3aa92384a45495691a6b4e5af27774e59a6ba4ae70747f98aea66c2122bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763444053,
      "headline": "Jim Cramer on Novo Nordisk: “You Gotta Let It Come Back a Little”",
      "id": 137522808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder of substantial NVO shares that have significantly declined in value, if it is too late to exit the position. In response, Mad Money’s host said: “You gotta, okay, you gotta let it come […]",
      "url": "https://finnhub.io/api/news?id=ff3a3aa92384a45495691a6b4e5af27774e59a6ba4ae70747f98aea66c2122bd"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch",
    "summary": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the rest of the branded pharmaceuticals stocks fared in Q3.",
    "url": "https://finnhub.io/api/news?id=51c5123229f2335fdf95acd5dbbd74a0a75814937f4e010b68b0e46bb1d77713",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763436788,
      "headline": "Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch",
      "id": 137538228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the rest of the branded pharmaceuticals stocks fared in Q3.",
      "url": "https://finnhub.io/api/news?id=51c5123229f2335fdf95acd5dbbd74a0a75814937f4e010b68b0e46bb1d77713"
    }
  },
  {
    "ts": null,
    "headline": "Alger Growth & Income Fund Q3 2025 Portfolio Update",
    "summary": "Class A shares of the Alger Growth & Income Fund outperformed the S&P 500 Index during the third quarter of 2025. Read more here.",
    "url": "https://finnhub.io/api/news?id=a9aed37ae53cd7ae0c3285035d1e9c5d6f8c5d7f6be69a78292dd1493d6b3bb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763432400,
      "headline": "Alger Growth & Income Fund Q3 2025 Portfolio Update",
      "id": 137524174,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Class A shares of the Alger Growth & Income Fund outperformed the S&P 500 Index during the third quarter of 2025. Read more here.",
      "url": "https://finnhub.io/api/news?id=a9aed37ae53cd7ae0c3285035d1e9c5d6f8c5d7f6be69a78292dd1493d6b3bb2"
    }
  }
]